Chapters

Transcript

Video

Given the refractoriness of platinum-resistant OC what does the investigational immunotherapy landscape look like for this patient subset with OC, including the use of immune checkpoint inhibitors and cytokine fusion proteins such as nemvaleukin?


Created by

CMEducation Resources | iQ&A Cytokine Immunotherapy Intelligence Zone

Presenter

John L. Hays, MD

John L. Hays, MD

Associate Professor, Department of Internal Medicine
Medical Director of the Clinical Trials Office
The Ohio State University College of Medicine
Wexner Medical Center & James Cancer Hospital
Columbus, OH